Crohn’s disease represents one of the most complex challenges in modern gastroenterology. It is an autoimmune inflammatory bowel disease in which the body’s immune system loses its ability to distinguish between self and non-self, indiscriminately attacking intestinal cells. This process triggers a cascade of devastating symptoms: intense abdominal pain, chronic bloody diarrhea, the formation of fistulas, abscesses, and deep ulcers. Furthermore, the disease is not limited to the digestive tract; it frequently affects other organs, such as the joints and eyes, further complicating the patient’s clinical profile.
In this context, a line of research has gained particular relevance in recent decades: the role of the endocannabinoid system. All the components necessary for cannabinoid function—CB1 and CB2 receptors, as well as endogenous ligands like anandamide—are naturally present in the digestive system. Science has shown that the expression of these elements differs significantly between healthy individuals and patients with Crohn’s, opening a promising therapeutic window to modulate inflammation and control symptoms.
In brief
- Mechanism of action: CB2 receptors in the intestinal mucosa play a crucial role in controlling inflammation and the symptoms associated with Crohn’s.
- Recent clinical evidence: A prospective clinical trial (2013) showed that smoked cannabis induced a complete response in half of the patients who responded poorly to steroids and immunomodulators.
- Risks associated with tobacco: Concomitant tobacco use is one of the worst prognostic factors for these patients, increasing the risk of infections and surgical complications.
- Routes of administration: Preliminary evidence suggests avoiding smoking in favor of alternatives like vaporization or oral/sublingual formulations to minimize lung damage.
- Need for more research: Long-term studies with larger numbers of participants and different cannabinoid ratios (THC, CBD, CBG) are required to optimize treatment.
Pathophysiology and the intestinal endocannabinoid system
To understand the potential utility of medical cannabis in this pathology, it is fundamental to understand how the immune system functions. Normally, this system acts as a vigilant guardian that eliminates external agents like bacteria or viruses. However, when it fails in its recognition function, it can attack the body’s own tissues, leading to autoimmune diseases. Crohn’s disease belongs to this group, alongside multiple sclerosis, rheumatoid arthritis, and type I diabetes.
The endocannabinoid system acts as an essential modulator in the body, regulating vital processes such as appetite, pain, mood, and—crucially for this article—inflammation. In a healthy intestine, cannabinoid receptors help maintain balance (homeostasis) and limit excessive inflammatory responses. In patients with Crohn’s, an alteration in this natural expression has been observed, suggesting that exogenous cannabinoid intervention could help partially restore this balance.
Clinical studies: What do the data say?
Although there have been anecdotal reports for decades from patients who experienced improvement with cannabis use, the scientific community has begun to validate these observations through controlled trials. A notable study published in 2013 by Naftali et al. offered a promising preliminary view.
The study involved twenty-one patients with severe Crohn’s disease who did not respond adequately to conventional treatment, which typically includes steroids and immunomodulators. Participants received marijuana cigarettes with a standardized content of 115 mg of THC twice daily for eight weeks, compared against a placebo (flowers from which the cannabinoids had been extracted).
The results were compelling: half of the patients treated with cannabis experienced a complete clinical response, and more than 90% reported some degree of improvement in their symptoms. Adverse effects were rare and considerably less significant than the benefit obtained by many participants. This finding ratifies the previous experiences of users and opens the door to more robust research.
On the other hand, a cross-sectional study conducted in 2014 by Storr et al. analyzed consumption habits in 313 patients evaluated at the University of Calgary’s Gastroenterology Service. The finding was that 18% of these patients had used cannabis to alleviate their symptoms during the previous year. The reported benefits were significant: reduction in abdominal pain (83.9%), cramps (76.8%), and diarrhea (28.6%).
It is important to note that this study also revealed a concerning correlation: surgical interventions were five times more frequent in the group of patients who used cannabis. However, it is crucial to interpret this with scientific caution. Statistical association does not imply direct causality. It is plausible that patients with more severe or refractory forms of the disease are the ones who turn to cannabis, and therefore, their higher surgical risk is due to the underlying severity of their pathology and not necessarily the consumption itself.
Risk reduction: Routes of administration and composition
One of the most critical aspects in the management of medical cannabis for patients with Crohn’s is the route of administration. There is scientific consensus that tobacco is one of the worst enemies of these patients. Cigarette smoke contains toxic and pro-inflammatory substances that aggravate the intestinal condition, increase the risk of infections, and worsen the general prognosis.
Therefore, any therapeutic strategy must prioritize avoiding combustion. Although current studies have focused on smoked cannabis due to its historical availability, vaporized, oral, or sublingual routes present significant theoretical advantages by eliminating exposure to smoke carcinogens and reducing the systemic impact of nicotine if it were present. The scientific community must continue researching to determine which route is the safest and most effective.
Furthermore, the chemical composition of the preparation is a determining factor. Although THC (tetrahydrocannabinol) has proven effective in several studies, it cannot be ruled out that other cannabinoids like CBD (cannabidiol), CBG, or THCV have complementary or superior roles in certain contexts. Cannabigerol and tetrahydrocannabivarin have shown anti-inflammatory properties in animal models. The search for the “optimal ratio” or the ideal preparation remains a pending objective that requires larger clinical trials.
Editorial conclusion
Crohn’s disease is a complex condition that profoundly affects the quality of life of those who suffer from it. Emerging evidence suggests that cannabinoids may offer valuable symptomatic relief, especially in cases where conventional therapies have failed. However, it is imperative to approach this topic with scientific rigor and caution.
The use of cannabis should not be understood as a miracle cure or as an alternative to established medical treatments without professional supervision. Uncontrolled self-medication can lead to unpredictable consequences. The ideal approach is to foster harm reduction, where the patient and their medical team evaluate available therapeutic options together, always considering pulmonary safety by avoiding smoking and seeking preparations that maximize anti-inflammatory benefits.
Psiconáutica.org is committed to disseminating evidence-based information, promoting a culture of mental and physical health where scientific knowledge guides therapeutic decisions. Research on the endocannabinoid system is advancing rapidly, and we hope that future studies will further clarify its role in autoimmune diseases like Crohn’s, offering new tools to improve patients’ lives.
